Bessemer Group’s Lipocine LPCN Stock Holding History

Bessemer Group’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-105	Closed	-$7K	–	1762
2017 Q3	$7K	Hold	105	–	–	﹤0.01%	1631
2017 Q2	$7K	Buy	+105	New	+$6.85K	﹤0.01%	1638

Other funds holding LPCN

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DAM

DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Bessemer Group's LPCN Position: Q4 2017 in Review

Bessemer Group sold out of Lipocine (LPCN) in Q4 2017, closing a stake of 105 shares — an estimated $7K sold.

Bessemer Group first reported a position in LPCN in Q2 2017 and held it in 2 quarters. The position peaked at $7K in Q3 2017. 39 funds tracked by Wall St. Rank hold LPCN as of Q4 2017.

Bessemer Group reported no remaining Lipocine position as of Q4 2017 after selling out during the quarter.
Bessemer Group sold 105 Lipocine shares in Q4 2017, an estimated $7K.
Bessemer Group first reported a position in Lipocine in Q2 2017 and held it in 2 quarters.
Bessemer Group's Lipocine position peaked at $7K in Q3 2017.
39 funds tracked by Wall St. Rank held Lipocine as of Q4 2017.

Based on Bessemer Group's 13F filing for Q4 2017, filed 30 Jan 2018.